CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer

Cancer Immunology, Immunotherapy

Volumn 58, Issue 9, 2009, Pages 1441-1448

  Chikamatsu, Kazuaki ^a,b   Sakakura, Koichi ^a,c   Takahashi, Goro ^b   Okamoto, Atsushi ^b   Furuya, Nobuhiko ^a   Whiteside, Theresa L ^c   Deleo, Albert B ^c   Masuyama, Keisuke ^b  

^a GUNMA UNIVERSITY   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

CD4+ T cells; Head and neck cancer; P53; Th1; Th2

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HLA DP ANTIGEN; HLA DP5 ANTIGEN; INTERLEUKIN 5; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CELL POLARITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FEMALE; GENE SEQUENCE; HEAD AND NECK CANCER; HELPER CELL; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TH1 CELL; TH2 CELL;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HLA-DP ANTIGENS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON-GAMMA; INTERLEUKIN-5; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TH1 CELLS; TH2 CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67649671988     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0661-3     Document Type: Article

References (27)

1. J Bennouna A Hildesheim K Chikamatsu W Gooding WJ Storkus TL Whiteside 2002 Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses J Immunol Methods 261 145 156 (Pubitemid 34175224)
2. AP Black A Bailey L Jones RJ Turner K Hollowood GS Ogg 2005 p53-specific CD8+ T cell responses in individuals with cutaneous squamous cell carcinoma Br J Dermatol 153 987 991 (Pubitemid 41540766)
3. M Bueter M Gasser N Schramm T Lebedeva G Tocco C Gerstlauer M Grimm E Nichiporuk A Thalheimer A Thiede D Meyer G Benichou AM Waaga-Gasser 2006 T cell response to p53 tumor-associated antigen in patients with colorectal carcinoma Int J Oncol 28 431 438
4. 110-124-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells Cancer Res 63 3675 8361
5. G Consogno S Manici V Facchinetti A Bachi J Hammer BM Conti-Fine C Rugarli C Traversari MP Protti 2003 Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T cell epitopes on the tumor antigen MAGE-3 Blood 101 1038 1044 (Pubitemid 36139377)
6. LV Crawford DC Pim RD Bulbrook 1982 Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer Int J Cancer 30 403 408
7. AB DeLeo G Jay E Appella GC Dubois LW Law LJ Old 1979 Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse Proc Natl Acad Sci USA 76 2420 2424 (Pubitemid 9185501)
8. EV Fedoseyeva F Boisgerault NG Anosova WS Wollish P Arlotta PE Jensen SJ Ono G Benichou 2000 CD4+ T cell responses to self- and mutated p53 determinats during tumorigenesis in mice J Immunol 164 5641 5651 (Pubitemid 30389804)
9. H Fujita S Senju H Yokomizo H Saya M Ogawa S Matsushita Y Nishimura 1998 Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms Eur J Immunol 28 305 316 (Pubitemid 28048301)
10. S Gnjatic D Atanackovic E Jager M Matsuo A Selvakumar NK Altorki RG Maki B Dupont G Ritter YT Chen A Knuth LJ Old 2003 Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses Proc Natl Acad Sci USA 100 8862 8867 (Pubitemid 36899189)
11. P Hammel B Boissier MT Chaumette P Piedbois N Rotman JC Kouyoumdjian R Lubin JC Delchier T Soussi 1997 Detection and monitoring of serum p53 antibodies in patients with colorectal cancer Gut 40 356 361 (Pubitemid 27145649)
12. 264-272 peptide CD8 + T cells J Immunol 177 6795 6803 (Pubitemid 44715044)
13. KL Knutson ML Disis 2005 Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Cancer Immunol Imunother 54 721 728 (Pubitemid 40977140)
14. H Kobayashi M Wood Y Song E Appella E Celis 2000 Defining promiscuous MHC class II helper T cell epitopes for the HER2/neu tumor antigen Cancer Res 60 5228 5236 (Pubitemid 30739783)
15. M Mandic C Almunia S Vicel D Gillet B Janjic K Coval B Maillere JM Kirkwood HM Zarour 2003 The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactiveCD4+ T cells Cancer Res 63 6506 6515 (Pubitemid 37255204)
16. D Nagorsen U Keilholz L Rivoltini A Schmittel A Letsch AM Asemissen G Berger HJ Buhr E Thiel C Scheibenbogen 2000 Natural T cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer Cancer Res 60 4850 4854 (Pubitemid 30701499)
17. JM Rojas SEB McArdle RBV Horton M Bell S Mian G Li SA Ali RC Rees 2005 Peptide immunization of HLA-DR-transgenic mice permits the identification of a novel HLA-DRβ1*0101-and HLA-DRβ1*0401-restricted epitope from p53 Cancer Immunol Immunother 54 243 253 (Pubitemid 40174242)
18. K Sakakura K Chikamatsu N Furuya E Appella TL Whiteside AB DeLeo 2007 Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8+ T cell responses to HLA class I-restricted wild-type sequence p53 peptides Clin Immunol 125 43 51 (Pubitemid 47374535)
19. K Sakakura K Chikamatsu M Shino T Sakurai N Furuya 2006 Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: possible markers as predictors of clinical outcome Acta Otolaryngol 126 1295 1302 (Pubitemid 44764329)
20. T Soussi 2000 p53 antibodies in the sera of patients with various types of cancer: A review Cancer Res 60 1777 1788 (Pubitemid 30207629)
21. T Tatsumi CJ Herrem WC Olson JH Finke RM Bukowski MS Kinch E Ranieri WJ Storkus 2003 Disease stage variation in CD4+ and CD8 + T cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma Cancer Res 63 4481 4489 (Pubitemid 36951020)
22. AF Tilkin R Lubin T Soussi V Lazar N Janin MC Mathieu I Lefrere C Carlu M Roy M Kayibanda D Bellet JG Guillet B Bressac-de Paillerets 1995 Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer Eur J Immunol 25 1765 1769
23. SH van der Burg K de Cock AG Menon KLMC Franken M Palmen A Redeker JW Drijfhout PJK Kuppen CJH van de Velde L Erdile RAEM Tollenaar CJM Melief R Offringa 2001 Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer Eur J Immunol 31 146 155
24. SH van der Burg AG Menon A Redeker KLMC Franken JW Drijfhout RAEM Tollenaar HH Hartgrink CJH van de Velde PJK Kuppen CJM Melief R Offringa 2003 Magnitude and polarization of p53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors Int J Cancer 107 425 433 (Pubitemid 37266463)
25. RF Wang 2001 The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity Trends Immunol 22 269 276
26. JA Werner S Gottschlich BJ Folz T Goeroegh BM Lippert JD Maass H Rudert 1997 p53 serum antibodies as prognostic indicator in head and neck cancer Cancer Immunol Immunother 44 112 116 (Pubitemid 27198566)
27. G Zalcman B Schlichtholz J Tredaniel T Urban R Lubin I Dubois B Milleron A Hirsch T Soussi 1998 Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment Clin Cancer Res 4 1359 1366 (Pubitemid 28265217)